L-4-Chlorokynurenine (4-Cl-KYN; developmental code name AV-101) is an orally active small molecule prodrug of 7-chlorokynurenic acid, a NMDA receptor antagonist. It appears to be a rapid-acting antidepressant. AV-101 was discovered at Marion Merrell Dow and its biological activity was explored at University of Maryland. It underwent initial development at Artemis Neuroscience which was acquired by VistaGen in 2003. As of 2016, it was in a Phase II clinical trial for major depressive disorder . Research AV-101 showed efficacy in animal model of Huntington's disease and showed rapid-acting antidepressant effects similar to ketamine in the forced-swim test and two other behavioral models of depression in rodents. By 2013, AV-101 had successfully gone through two Phase I clinical trials. As of 2016, a Phase II clinical trial was underway in major depressive disorder. By 2019, a phase II clinical trial had shown negative results for major depressive disorder . It has been found to be effective for neuropathic painin animal studies .
L-4-Chlorokynurenine (4-Cl-KYN; developmental code name AV-101) is an orally active small molecule prodrug of 7-chlorokynurenic acid, a NMDA receptor antagonist. It was investigated as a potential rapid-acting antidepressant. AV-101 was discovered at Marion Merrell Dow and its biological activity was explored at University of Maryland. It underwent initial development at Artemis Neuroscience which was acquired by VistaGen in 2003. A phase II clinical trial failed to show any effect over placebo in alleviating treatment-resistant depression . Research By 2013, AV-101 had successfully gone through two Phase I clinical trials. In 2016, a Phase II clinical trial was initiated to assess AV-101 in treatment-resistant major depression. The trial found no difference in treatment effects between AV-101 and placebo . Preclinical studies in animal models suggested efficacy in treating neuropathic pain. AV-101 showed efficacy in an animal model of Huntington's disease and rapid-acting antidepressant effects similar to ketamine in behavioral models of depression in rodents .
R
appears to be a
was investigated as a potential
R
As of 2016, it was in a Phase
A phase
R
for major depressive disorder
failed to show any effect over placebo in alleviating treatment-resistant depression
D
AV-101 showed efficacy in animal model of Huntington's disease and showed rapid-acting antidepressant effects similar to ketamine in the forced-swim test and two other behavioral models of depression in rodents.
R
As of
In
D
underway in major depressive disorder.
R
By 2019, a phase II clinical trial had shown negative results for major depressive disorder
initiated to assess AV-101 in treatment-resistant major depression. The trial found no difference in treatment effects between AV-101 and placebo
R
It has been found to be effective for neuropathic painin animal studies
Preclinical studies in animal models suggested efficacy in treating neuropathic pain. AV-101 showed efficacy in an animal model of Huntington's disease and rapid-acting antidepressant effects similar to ketamine in behavioral models of depression in rodents